ATR Inhibitors and Paclitaxel in Melanoma

被引：8
作者：
Ashworth, Alan [1 ]
机构：
[1] UCSF Helen Diller Family Comprehens Canc Ctr, 1450 3rd St, San Francisco, CA 94158 USA
来源：
CLINICAL CANCER RESEARCH | 2021年 / 27卷 / 17期
关键词：
D O I：
10.1158/1078-0432.CCR-21-1778
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A phase I study defined a tolerable combination of the ATR inhibitor ceralasertib with paclitaxel and responses were seen in patients with melanoma who had progressed on an immune check-point inhibitor. This combination warrants further exploration to determine the extent and molecular determinants of clinical activity.
引用
收藏
页码：4667 / 4668
页数：2
相关论文
共 6 条
  • [1] The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
    Bastian, Boris C.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9, 2014, 9 : 239 - 271
  • [2] A potent Chkl inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress
    Brooks, K.
    Oakes, V.
    Edwards, B.
    Ranall, M.
    Leo, P.
    Pavey, S.
    Pinder, A.
    Beamish, H.
    Mukhopadhyay, P.
    Lambie, D.
    Gabrielli, B.
    [J]. ONCOGENE, 2013, 32 (06) : 788 - 796
  • [3] A mitosis-specific and R loop-driven ATR pathway promotes faithful chromosome segregation
    Kabeche, Lilian
    Nguyen, Hai Dang
    Buisson, Remi
    Zou, Lee
    [J]. SCIENCE, 2018, 359 (6371) : 108 - 113
  • [4] Molecular Pathways: Targeting ATR in Cancer Therapy
    Karnitz, Larry M.
    Zou, Lee
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4780 - 4785
  • [5] Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer
    Kim, Seung Tae
    Smith, Simon A.
    Mortimer, Peter
    Loembe, Arsene-Bienvenu
    Cho, Heejin
    Kim, Kyoung-Mee
    Smith, Claire
    Willis, Sophie
    Irurzun-Arana, Itziar
    Berges, Alienor
    Hong, Jung Yong
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Kozarewa, Iwanka
    Pierce, Andrew J.
    Dean, Emma
    Lee, Jeeyun
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4700 - 4709
  • [6] PARP inhibitors: Synthetic lethality in the clinic
    Lord, Christopher J.
    Ashworth, Alan
    [J]. SCIENCE, 2017, 355 (6330) : 1152 - 1158
1